Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy

Seminars in Nephrology

Volumn 24, Issue 3, 2004, Pages 218-224

  Dillon, John J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; TRANDOLAPRIL;

ALLELE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DISEASE COURSE; DISEASE PREDISPOSITION; DIZZINESS; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENOTYPE; HUMAN; HYPERKALEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 2542489413     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2004.01.003     Document Type: Article

References (52)

1. D'Amico G: Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36:227-237, 2000
2. Haas M: Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis 29:829-842, 1997
3. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
4. Remuzzi A, Perico N, Sangalli F, et al: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 276:F457-466, 1999
5. Remuzzi G, Perna A, Benigni A: Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Contrib Nephrol 118:164-172, 1996
6. Perna A, Remuzzi G: Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. Am J Kidney Dis 27:34-41, 1996
7. Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60:1131-1140, 2001
8. Hernandez E, Toledo T, Alamo C, et al: Elevation of von Willebrand factor levels in patients with IgA nephropathy: Effect of ACE inhibition. Am J Kidney Dis 30:397-403, 1997
9. Maschio G, Cagnoli L, Claroni F, et al: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 9:265-269, 1994
10. Remuzzi A, Perticucci E, Ruggenenti P, et al: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 39:1267-1273, 1991
11. Perico N, Remuzzi A, Sangalli F, et al: The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9:2308-2317, 1998
12. Russo D, Pisani A, Balletta MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
13. Laverman GD, Navis G, Henning RH, et al: Dual reninangiotensin system blockade at optimal doses for proteinuria. Kidney Int 62:1020-1025, 2002
14. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
15. Feriozzi S, Pierucci A, Roscia E, et al: Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens Suppl 7:S63-64, 1989
16. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247-254, 1994
17. Bannister KM, Weaver A, Clarkson AR, et al: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 111:184-193, 1995
18. Maschio G, Alberti D, Locatelli F, et al: Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 33: S16-20discussion S41-43, 1999
19. Ruggenenti P, Perna A, Mosconi L, et al: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53:1209-1216, 1998
20. Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
21. Ruggenenti P, Perna A, Gherardi G, et al: Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155-1165, 2000
22. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
23. Lewis EJ, Hunsicker LG, Bain RP: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [erratum appears in N Engl J Med 1993;330:152]: N Engl J Med 329:1456-1462, 1993
24. Lewis EJ, Hunsicker LG, Bain RP: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [erratum appears in N Engl J Med 1993;330:152]: N Engl J Med 329:1456-1462, 1993
25. Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38:18-25, 2001
26. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial [erratum appears in Lancet 2003;361:1230]. Lancet 361:117-124, 2003
27. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial [erratum appears in Lancet 2003;361:1230]. Lancet 361:117-124, 2003
28. Jacobsen P, Andersen S, Jensen BR, et al: Additive Effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14:992-999, 2003
29. Lacourciere Y, Belanger A, Godin C, et al: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 58:762-769, 2000
30. Mogensen CE, Neldam S, Tikkanen I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000
31. Bhattacharjee R, Filler G: Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol 17:302-304, 2002
32. Ruilope LM, Aldigier JC, Ponticelli C, et al: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89-95, 2000
33. Tiret L, Rigat B, Visvikis S, et al: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51:197-205, 1992
34. Yoshida H, Mitarai T, Kawamura T, et al: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96:2162-2169, 1995
35. Pei Y, Scholey J, Thai K, et al: Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 100:814-820, 1997
36. Yorioka T, Suehiro T, Yasuoka N, et al: Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol 44:80-85, 1995
37. Tanaka R, Iijima K, Murakami R, et al: ACE gene polymorphism in childhood IgA nephropathy: Association with clinicopathologic findings. Am J Kidney Dis 31:774-779, 1998
38. Hunley TE, Julian BA, Phillips JA III, et al: Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 49:571-577, 1996
39. Santos NM, Ault BH, Gharavi AG, et al: Angiotensin-converting enzyme genotype and outcome in pediatric IgA nephropathy. Pediatr Nephrol 17:496-502, 2002
40. Lau YK, Woo KT, Choong HL, et al: ACE gene polymorphism and disease progression of IgA nephropathy in Asians in Singapore. Nephron 91:499-503, 2002
41. Schena FP, D'Altri C, Cerullo G, et al: ACE gene polymorphism and IgA nephropathy: An ethnically homogeneous study and a meta-analysis. Kidney Int 60:732-740, 2001
42. Suzuki S, Suzuki Y, Kobayashi Y, et al: Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy. Am J Kidney Dis 35:896-903, 2000
43. Ong-Ajyooth S, Ong-Ajyooth L, Limmongkon A, et al: The renin-angiotensin system gene polymorphisms and clinicopathological correlations in IgA nephropathy. J Med Assoc Thai 82:681-689, 1999
44. Zhu X, Bouzekri N, Southam L, et al: Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 68:1139-1148, 2001
45. Wang JG, Staessen JA: Genetic polymorphisms in the renin-angiotensin system: Relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 410:289-302, 2000
46. Fogarty DG, Harron JC, Hughes AE, et al: A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 45:1204-1208, 1996
47. Prasad GV, Pinnaduwage D, Parkes RK, et al: Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction. Transplantation 75:209-216, 2003
48. Maruyama K, Yoshida M, Nishio H, et al: Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy. Pediatr Nephrol 16:350-355, 2001
49. Goto S, Narita I, Saito N, et al: A(-20)C polymorphism of the angiotensinogen gene and progression of IgA nephropathy. Kidney Int 62:980-985, 2002
50. Frimat L, Philippe C, Maghakian MN, et al: Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS-A study of 274 men. J Am Soc Nephrol 11:2062-2067, 2000
51. Perna A, Ruggenenti P, Testa A, et al: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathiesl. Kidney Int 57:274-281, 2000
52. Praga M, Gutierrez E, Gonzalez E, et al: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14:1578-1583, 2003